US Stock Market Move | Income guidance for 2026 lower than expected BioNTech (BNTX.US) plunges more than 20%

On Tuesday, BioNTech (BNTX.US) plummeted more than 20% in early trading, marking the largest drop since April 25th, and is currently trading at $80.20. On the news front, the company's previously announced fourth-quarter adjusted loss and 2026 full-year revenue guidance were both below analysts' expectations. The company reported a diluted adjusted loss per share of 0.33 euros for the fourth quarter, compared to a profit per share of 1.79 euros a year ago. Analysts surveyed by FactSet had expected a loss per share of 0.16 euros. Quarterly revenue as of December 31 was 907.4 million euros, down from 1.19 billion euros a year ago. Analysts surveyed by FactSet had expected revenue of 768.3 million euros. For 2026, the company expects revenue to be between 2 to 2.3 billion euros, while analysts surveyed by FactSet projected revenue of 2.75 billion euros. In addition, the founders of BioNTechSE will be leaving the company to start a new biotechnology company focused on messenger RNA (mRNA) technology, which is the core technology of their popular COVID-19 vaccine.